




The relative strengths and weaknesses of Zevra Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zevra Therapeutics INC compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 5.6% points. The greatest weakness of Zevra Therapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 198% points.

The company's Economic Capital Ratio, given in the ranking table, is 41%, being 197% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	6,634
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,431
Liabilities, Non-Current	2,069
Other Assets	2,402
Other Compr. Net Income	0
Other Expenses	2,923
Other Liabilities	77,463
Other Net Income	-4,207
Other Revenues	12,839
Property and Equipment	1,471
Research and Development	19,415
Selling, General and Administrative Expense	10,816

Output Variable	Value in 1000 USD
Assets	10,507
Liabilities	84,963
Expenses	33,154
Revenues	12,839
Stockholders Equity	-74,456
Net Income	-24,522
Comprehensive Net Income	-24,522
BaseVar	72,835
ECR before LimitedLiability	-391%
Economic Capital Ratio	41%